CD33 and acute myeloid leukemia: Gemtuzumab ozogamicin (GO), an anti‐CD33 immunoconjugate, has the unique distinction of being the first targeted agent in AML that was approved by the FDA via accelerated approval in 2000 for older patients with AML in first relapse 11.